1,721,027 research outputs found
Quantitative Aspects of Pinocytosis and the Intracellular Fate of N-acetyl-α-D-glucosaminidase in Sanfilippo B Fibroblasts
No full textThe cellular uptake of N-acetyl-α-D-glucosaminidase, the deficient enzyme in Sanfilippo B disease, and the intracellular fate and metabolic effect of this enzyme have been investigated in Sanfilippo B and normal fibroblasts. For both-genotypes the uptake is highly efficient (up to 0.025 mU/h/mg cell protein), specific and constant over a period of at least 6 days. It is probable that the enzyme protein is taken up by adsorptive pinocytosis. The enzymatic activity as well as the biological activity towards 'SO4-labeled mucopolysaccharides persist in Sanfilippo B cells with a half-life of 34 h, indicating the intralysosomal localization of the pinocytosed enzyme. The data obtained are discussed with regard to a possible enzyme replacement therapy. For Sanfilippo B disease the doses used in the past are considered to be insufficient to cause measurable effects
Quantitative Aspects of Pinocytosis and the Intracellular Fate of N-acetyl-α-D-glucosaminidase in Sanfilippo B Fibroblasts
No full textThe cellular uptake of N-acetyl-α-D-glucosaminidase, the deficient enzyme in Sanfilippo B disease, and the intracellular fate and metabolic effect of this enzyme have been investigated in Sanfilippo B and normal fibroblasts. For both-genotypes the uptake is highly efficient (up to 0.025 mU/h/mg cell protein), specific and constant over a period of at least 6 days. It is probable that the enzyme protein is taken up by adsorptive pinocytosis. The enzymatic activity as well as the biological activity towards 'SO4-labeled mucopolysaccharides persist in Sanfilippo B cells with a half-life of 34 h, indicating the intralysosomal localization of the pinocytosed enzyme. The data obtained are discussed with regard to a possible enzyme replacement therapy. For Sanfilippo B disease the doses used in the past are considered to be insufficient to cause measurable effects
Sanfilippo B disease: Serum assays for detection of homozygous and heterozygous individuals in three families
No full textThree assays for the determination of N-acetyl-α- -D-glucosaminidase activity in the serum are described. In three families with patients suffering from Sanfilippo B disease, the affected individuals had a residual enzyme activity in the range of 2 to 16 per cent that of normal control subjects. Their obligate heterozygous parents had an activity diminished to 26 to 35 per cent. Nine other members of these families had enzyme activities lowered to the same extent and were therefore considered to be heterozygous carriers of the Sanfilippo B gene
Sanfilippo B disease: Serum assays for detection of homozygous and heterozygous individuals in three families
No full textThree assays for the determination of N-acetyl-α- -D-glucosaminidase activity in the serum are described. In three families with patients suffering from Sanfilippo B disease, the affected individuals had a residual enzyme activity in the range of 2 to 16 per cent that of normal control subjects. Their obligate heterozygous parents had an activity diminished to 26 to 35 per cent. Nine other members of these families had enzyme activities lowered to the same extent and were therefore considered to be heterozygous carriers of the Sanfilippo B gene
Generation of two NAGLU-mutated homozygous cell lines from healthy induced pluripotent stem cells using CRISPR/Cas9 to model Sanfilippo B syndrome
Full text linkMutations in the NAGLU gene cause Sanfilippo B syndrome (mucopolysaccharidosis IIIB), a rare lysosomal storage disorder whose main symptom is a severe and progressive neurodegeneration for which no treatment is still available. Here, we generated two homozygous NAGLU-mutated cell lines using CRISPR/Cas9 editing in a healthy human induced pluripotent stem cell (hiPSC) line. These novel cell lines express pluripotency specific markers and maintain their capability to differentiate into all three germ layers in vitro while exhibit a normal karyotype. These mutated lines in combination with the isogenic control line will be useful to model in vitro Sanfilippo B syndrome
Cloning and Expression of the Gene Involved in Sanfilippo B Syndrome (Mucopolysaccharidosis III B)
No full textSanfilippo B syndrome is caused by a deficiency of alpha-N-acetylglucosaminidase, a lysosomal enzyme involved in the degradation of heparan sulphate. Accumulation of the substrate in lysosomes results in degeneration of the central nervous system with progressive dementia often combined with hyperactivity and aggressive behaviour. In order to clone the deficient gene, we purified the enzyme from human placenta and obtained amino acid sequence information. Alignment of one of the CNBr generated internal peptides to sequence from the database revealed the chromosomal location of the gene in the 5' upstream flanking region of the gene for 17-beta-hydroxysteroid-dehydrogenase at 17q21.1. The available DNA sequence was used to clone the cDNA coding for alpha-N-acetylglucosaminidase and analyse its gene structure. The gene is fully contained in the 5' upstream flanking region of the gene for 17-beta-hydroxysteroid-dehydrogenase and interrupted by five introns. The cDNA clone has a length of 2575 bp and encodes a protein of 743 amino acids. Chinese hamster ovary cells transfected with the cDNA construct show alpha-N-acetylglucosaminidase activity about 17-fold over background. This will allow correction studies with NAG deficient Sanfilippo B cell lines and facilitate the development of enzyme replacement therapy for these patients
Sanfilippo B syndrome (MPS III B): case report with analysis of CSF mucopolysaccharides and conjunctival biopsy
No full textA case of a child with Sanfilippo B syndrome (MPS III B), born of a consanguineous marriage, is reported. Urinary mucopolysaccharide analysis showed an abnormal excretion mainly of heparan sulphate. N-acetyl-a-glucosaminidase activity was absent in the patient but was present in the heterozygous range in parents and siblings. CSF mucopolysaccharides were also abnormally high. In fibrocytes from conjunctival biopsy and CSF cells numerous vacuoles containing storage material were found. The presence of vacuoles in fibrocytes from conjunctival biopsy and/or in CSF cells can be useful in the diagnosis of many suspected lysosomal storage disorders
Pathophysiological cascades of Sanfilippo B disease
No full textLa mucopolysaccharidose de type IIIB (MPSIIIB), ou maladie de Sanfilippo B, est une maladie de surcharge lysosomale caractérisée par des atteintes neurologiques. Cette maladie génétique rare est causée par la déficience en a-N-acétylglucosaminidase (NAGLU), une enzyme nécessaire pour la dégradation des héparanes sulfates (HS). La dégradation incomplète des HS cause l’accumulation de saccharides d’HS dans les lysosomes et à la surface des cellules. Mais la cascade physiopathologique induite par ces saccharides n’est pour l’instant pas connue. D’une part, ces recherches fournissent des preuves que la communication avec l’environnement des cellules neurales déficientes en NAGLU est altérée. En effet, l’intégrine ß1 et ses effecteurs sont suractivés et recrutés au niveau des plaques d’adhérence dans des astrocytes déficients. Les comportements cellulaires dépendants des intégrines, tels que la polarisation et la migration, sont également altérés. Ces phénotypes sont restaurés par l’apport de l’enzyme déficiente. Cette restauration indique que l’accumulation de saccharides d’HS provoque l’activation de la signalisation des intégrines, et perturbe la polarisation et la migration des cellules neurales. L’ajout de saccharides d’HS purifiés sur des cellules neurales normales confirme que les saccharides d’HS extracellulaires activent des composants des plaques d’adhérence. D’autre part, l’étude d’un modèle cellulaire humain, dont l’expression de NAGLU a été inhibée par shRNA, a montré que l’accumulation de vésicules de stockage caractéristiques de la maladie est causée, entre autre, par une déformation de l’appareil de Golgi et la surexpression de GM130. Ces phénotypes sont également observés dans les neurones atteints. Ils s’accompagnent d’une augmentation de la stabilité et de la nucléation des microtubules, au niveau de l’appareil de Golgi. Les défauts de communication entre la cellule malade et son environnement semblent donc modifier la dynamique et la structure cellulaire. Nous présumons que les mécanismes physiopathologiques déchiffrés en culture sont reliés à la neuropathologie de la MPSIIIB. En perturbant la perception de l’environnement cellulaire, la polarité, la migration, et la pousse neuritique, les saccharides d’HS accumulés dans les tissus cérébraux malades, affectent probablement divers mécanismes clefs de la maturation corticale.Mucopolysaccharidosis type IIIB (Sanfilippo B disease) is a lysosomal storage disease characterized by severe neurological manifestations in children. This rare monogenic disease is caused by a-Nacetylglucosaminidase (NAGLU) deficiency, a lysosomal hydrolase necessary for heparan sulfate (HS) degradation. This deficiency leads to the accumulation of HS saccharides. Mechanisms mediating HS saccharides deleterious effects on brain cells are not well understood. This research provides evidences that neural cell sensing of environment is altered in MPSIIIB cells. Integrins and focal adhesion components are over-recruited and over-activated in deficient mouse astrocytes. Consistently, integrin-dependant cell behavior such as cell polarization and directed migration were defective in affected astrocytes and neural stem cells. HS saccharide clearance, by NAGLU gene transfer, rescues a normal phenotype suggesting that HS saccharides induce focal adhesion formation. Addition of purified HS saccharides on normal astrocytes confirms that extracellular HS saccharides can activate the recruitment of focal adhesion components and provides an in vitro assay to decipher the saccharide code of HS. Otherwise, investigations performed on HeLa cell model, in which NAGLU expression was inhibited by shRNA, showed that accumulation of intracellular storage vesicles, a hallmark of the disease, is due over expression of a cis-Golgi protein. This affects the Golgi morphology and microtubule nucleation and stability. It seems that alterations of environment cell sensing and downstream signaling also modify the dynamic and the structure of cells. We assume that mechanisms deciphered in cell cultures are related to MPSIIIB neuropathology. By affecting cell perception of environmental cues, cell polarity, cell migration and neurite outgrowth, HS saccharides, which accumulate in brain tissues defective for a HS degradation enzyme, likely affect various processes important for accurate cortical maturation
Intracerebral Gene Therapy in Four Children with Sanfilippo B Syndrome: 5.5-Year Follow-Up Results
No full textInternational audienceWe report the safety (primary endpoint) and efficacy (secondary endpoint) of a novel intracerebral gene therapy at 5.5 years of follow-up in children with Sanfilippo B. An uncontrolled, phase 1/2 clinical trial was performed in four patients aged 20, 26, 30, and 53 months. Treatment consisted of 16 intracerebral and cerebellar deposits of a recombinant adeno-associated viral vector encoding human α-N-acetylglucosaminidase (rAAV2/5-hNAGLU) plus immunosuppression. An intermediate report at 30 months was previously published. Thirty treatment-emergent adverse events were reported between 30 and 66 months after surgery, including three classified as severe with no serious drug reactions. At 5.5 years, NAGLU activity was persistently detected in the lumbar cerebrospinal fluid (18% of unaffected control level). Circulating T cells reacting against NAGLU peptides were present, indicating a lack of acquired tolerance. Patients 2, 3, and 4 showed progressive brain atrophy and neurocognitive evolution that did not differ from untreated Sanfilippo A/B children. Patient 1, enrolled at 20 months of age, had a milder disease with normal brain imaging and a significantly better cognitive outcome than the three other patients and untreated patients, although not equivalent to normal children. After 5.5 years, the primary endpoint of this study was achieved with a good safety profile of the proposed treatment. We have also observed sustained enzyme production in the brain and absence of immunological tolerance. Cognitive benefit was not confirmed in the three oldest patients. Milder disease in the youngest patient supports further investigations of adeno-associated vector-mediated intracerebral gene therapy in Sanfilippo B
Intracerebral Gene Therapy in Four Children with Sanfilippo B Syndrome: 5.5-Year Follow-Up Results
No full textWe report the safety (primary endpoint) and efficacy (secondary endpoint) of a novel intracerebral gene therapy at 5.5 years of follow-up in children with Sanfilippo B. An uncontrolled, phase 1/2 clinical trial was performed in four patients aged 20, 26, 30, and 53 months. Treatment consisted of 16 intracerebral and cerebellar deposits of a recombinant adeno-associated viral vector encoding human α-N-acetylglucosaminidase (rAAV2/5-hNAGLU) plus immunosuppression. An intermediate report at 30 months was previously published. Thirty treatment-emergent adverse events were reported between 30 and 66 months after surgery, including three classified as severe with no serious drug reactions. At 5.5 years, NAGLU activity was persistently detected in the lumbar cerebrospinal fluid (18% of unaffected control level). Circulating T cells reacting against NAGLU peptides were present, indicating a lack of acquired tolerance. Patients 2, 3, and 4 showed progressive brain atrophy and neurocognitive evolution that did not differ from untreated Sanfilippo A/B children. Patient 1, enrolled at 20 months of age, had a milder disease with normal brain imaging and a significantly better cognitive outcome than the three other patients and untreated patients, although not equivalent to normal children. After 5.5 years, the primary endpoint of this study was achieved with a good safety profile of the proposed treatment. We have also observed sustained enzyme production in the brain and absence of immunological tolerance. Cognitive benefit was not confirmed in the three oldest patients. Milder disease in the youngest patient supports further investigations of adeno-associated vector-mediated intracerebral gene therapy in Sanfilippo B
- …
